Novel Integrin-Specific Targets for Anti-Platelet Therapies

Author(s): Aisling Robinson, Sarah O'Neill, Niamh Moran.

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 14 , 2004

Abstract:

Extensive study in integrin research has seen the platelet specific receptor αIIbβ3 (Glycoprotein GPIIb / IIIa) under much scrutiny, and provided vast information as to the workings of this integrin within the blood. Glanzmanns thrombasthenia, a rare autosomal recessive bleeding disorder, highlights the vital role played by this receptor in platelet function [1]. Glanzmanns thrombasthenic platelets fail to aggregate due to a lack of surface expression of functional aIIb or β3 on the platelet surface. However, little is known about the precise molecular mechanisms involved in the operation of this receptor on the platelet surface. Clinical trials using intravenous antagonists to this receptor have shown them to be effective anti-thrombotics. However the recent observations that the oral αIIbβ3 antagonists have failed to show benefits in the treatment of acute coronary syndromes, and in fact, increase mortality, underscores the necessity for a more complete understanding of aIIbb3 and its functions [2, 3]. A more profound knowledge of the precise nature of the platelet integrin-activation, along with an understanding of its interactions with cellular signaling proteins, will undoubtedly lead to the identification of novel strategies for the effective inhibition of platelet integrin function.

Keywords: anti-platelet therapies, integrin, glycoprotein, glanzmanns thrombasthenia, autosomal recessive bleeding disorder

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 14
Year: 2004
Page: [1603 - 1609]
Pages: 7
DOI: 10.2174/1381612043384628
Price: $58

Article Metrics

PDF: 1